Antibody treatment found to cut Covid hospitalisation risk

Sep 17, 2020
New York Raising hope of Covid-19 treatment at an early stage, an antibody therapy has been found to quickly reduce SARS-CoV-2 viral load in newly infected patients and cut hospitalisation risk, US-based pharmaceutical company Eli Lilly said, while revealing interim results of a clinical trial.

The Phase 2 study of the BLAZE-1 clinical trial evaluated LY-CoV555, a SARS-CoV-2 neutralising antibody, for the treatment of symptomatic Covid-19 in the outpatient setting, the company said on Wednesday.

The trial enrolled mild-to-moderate recently diagnosed Covid-19 patients across four groups –placebo, 700 mg, 2800 mg, and 7000 mg.

Analyses of viral data demonstrated that LY-CoV555 improved viral clearance at an earlier time point — day 3 — and reduced the proportion of patients with persistently high viral load at later time points.

Most study hospitalisations occurred in patients with underlying risk factors — age or body mass index (BMI) — suggesting a more pronounced treatment effect for patients in these higher-risk groups.

Ongoing studies will seek to confirm this finding, the drugmaker said.

Across all treatment groups, including placebo, no patients progressed to mechanical ventilation or died, the results showed.

Exploratory analyses indicated a more rapid improvement in symptoms for patients treated with LY-CoV555 versus placebo, supporting the hospitalisation effect.

The treatment was well-tolerated, with no drug-related serious adverse events reported.

“These interim data from the BLAZE-1 trial suggest that LY-CoV555, an antibody specifically directed against SARS-CoV-2, has a direct antiviral effect and may reduce Covid-related hospitalisations,” Daniel Skovronsky, Lilly’s chief scientific officer and president of Lilly Research Laboratories, said in a statement.

“The results reinforce our conviction that neutralising antibodies can help in the fight against Covid-19.”

The company said it intends to quickly publish the results of this interim analysis in a peer-reviewed journal and discuss appropriate next steps with global regulators.

If proved to be effective in further analyses, this could be the first potential treament for Covid-19 patients with mild and moderate level of severity.

This is because the drug remdesivir and the steroid dexamethasone have been found to be helpful in treatment of patients with serious illness.

The BLAZE-1 clinical trial remains ongoing, testing LY-CoV555 in combination with a second Lilly antibody, LY-CoV016, which binds a different epitope in the SARS-CoV-2 spike region.A

The trial is currently enrolling a larger, confirmatory cohort of higher risk patients, testing the ability of the antibody combination to reduce the number of patients with persistently high viral load and reduce Covid-related hospitalisations.IANS

No link between vaccination and sudden cardiac death in youth: Dr Randeep Guleria

New Delhi: Former AIIMS Director Dr Randeep Guleria on Friday said that recent studies by ICMR and AIIMS have clearly shown there is no link between COVID-19 vaccination and sudden...

ICMR, AIIMS studies found no link between Covid vaccine & sudden deaths: Centre

New Delhi: Extensive studies undertaken by the Indian Council of Medical Research (ICMR), and All India Institute of Medical Sciences (AIIMS) have conclusively established no link between Covid-19 vaccines and...

US foreign aid cuts can lead to over 14 mn preventable deaths globally by 2030: Lancet

New Delhi: The dismantling of US foreign aid, imposed by the Donald Trump government, can lead to more than 14 million additional deaths by 2030, including over 4.5 million children...

Infections due to new Covid strains not severe, we’re monitoring: ICMR-NIV Director

Pune: The JN.1.16 sub lineage of Omicron variant and the XFG (LF.7 and LP.81.2) recombinant variant did not cause much severe Covid infection, said Dr Naveen Kumar, Director ICMR-National Institute...

Covid-19 virus protein triggers immune attack on healthy cells: Study

New Delhi: Amid a fresh wave of Covid-19, Israeli researchers have discovered that a protein from the SARS-CoV-2 virus can cause the immune system to attack healthy cells mistakenly. The...

Gujarat records 235 new Covid cases, health officials advise precautions

Ahmedabad: Gujarat has recorded over 1,100 active cases of Covid-19, with 235 reported in the last 24 hours, said officials here on Tuesday, adding that there is no need to...

Five die at govt hospital in Odisha due to ‘medical negligence’, probe ordered

Bhubaneswar: At least five patients died in the government-run Saheed Laxman Nayak Medical College and Hospital (SLNMCH) in Odisha's Koraput after being administered "wrong injection". A probe has been ordered...

Covid-19 cases in Gujarat cross 460 mark: Ahmedabad sees fourfold rise in a week

Ahmedabad: Gujarat recorded 64 Covid-19 cases in the past 24 hours, bringing the total number of infections to 461. Of the 461 active cases, only 20 patients are currently undergoing...

Study shows how plastic particles in food, beverages can harm your liver

New Delhi: Microscopic plastic particles found in food and beverages may affect glucose metabolism and harm organs such as the liver, according to a new animal study. The findings raise...

Covid cases rise in India; govt says monitoring the situation

New Delhi: Amid the latest wave of Covid-19, the number of SARS-CoV2 infections in the country has risen to 2,170. As many as 511 new cases were recorded from the...

Food companies must not use ‘100pc’ claim in labelling and promotions: FSSAI

New Delhi: The Food Safety and Standards Authority of India (FSSAI) has issued a strong advisory to food companies against the use of the term "100 per cent" in food...

Chennai reports Covid-19 fatality as 60-year-old dies at Rajiv Gandhi government hospital

Chennai: A 60-year-old man undergoing treatment for Covid-19 at the Rajiv Gandhi Government General Hospital (RGGGH) in Chennai passed away on Wednesday, marking a Covid-linked fatality in the city after...

Read Previous

Nobody cured due to ‘Bhabhiji papad’: Shiv Sena attacks Centre

Read Next

In a rare case, Bangladesh issues demarche to India on ban of onion export

WP2Social Auto Publish Powered By : XYZScripts.com